Dornase Alfa and Cisplatin for resistant germ cell cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, dornase alfa and cisplatin, for men with germ cell cancer that has not responded to standard treatments or has come back. The goal is to see if this new combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have germ cell cancer (seminoma or non-seminoma) that started outside the brain and cannot be cured with surgery or standard chemotherapy.
- Your cancer must have come back or not responded after at least two rounds of chemotherapy, or after high-dose chemotherapy, or you must be unable to have high-dose chemotherapy.
- You must have tumors that can be measured on scans and rising tumor markers in your blood.
- You need to be in fairly good health (able to do daily activities) with adequate blood cell counts, liver and kidney function.
- You must be willing to use effective birth control during the study and for 6 months after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
Hear when a new Refractory Germ Cell Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.